Please fill out the form. We’ll be in touch as soon as possible.
Long Term Products
*Therapeutic: 78% Success In Treating IBS, IBS Management Service On Sale, %83 Success In Treating Chronic Constipation
ENBIOSIS generic framework gathers microbiome samples and lifestyle&health information by mail-in-kits or on-site from the users via a panel of applications. The samples are subject to next-generation sequencing and the data generated are placed in the biobank to be mined by AI algorithms to return the specific solutions. This generalized pipeline applicable to a range of add-on solutions sharing the same operation system.
In the background, several machine learning agents (metagenomic biomarker discoverers) constantly mine the evergrowing biobank, consisting of the sequenced data, electronic health&lifestyle records, and biological samples collected. These agents are multiple copies of AI miners searching for microbiome markers associated with human health. Their discoveries define the next-line of applications that is to use the very same service framework.
In-house & Protected
Patent & Licences
• Data-driven novel biomarkers
• SOTA non-invasive diagnostics
• Microbiome based health network supported by ENBIOSIS Biobank
• Unified platform for a spectrum of applications
New generic probiotics
Diagnosis of heart diseases based on blood microbiome
Diagnosis of gastrointestinal diseases based on gut microbiome
Diagnosis of non-alcoholic fatty liver diseases based on stool microbiome
Microbiome Medication Efficacy interaction
Phase 2 - 3
*The abstract of our clinical study on IBS management is now available in Gastroenterology (Impact factor 17).
We intend to expand our business by introducing new products that will be the result of an extensive research.